> Detailanzeige

Ocio, Enrique M.; Sanchez‐Guijo, Fermin M.; Diez‐Campelo, Maria; Castilla, Cristina; Blanco, Oscar J.; Caballero, Dolores; San Miguel, Jesus F.

Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena
  • Beteiligte: Ocio, Enrique M.; Sanchez‐Guijo, Fermin M.; Diez‐Campelo, Maria; Castilla, Cristina; Blanco, Oscar J.; Caballero, Dolores; San Miguel, Jesus F.
  • Erschienen: Wiley, 2005
  • Erschienen in: American Journal of Hematology, 78 (2005) 4, Seite 302-305
  • Sprache: Englisch
  • DOI: 10.1002/ajh.20283
  • ISSN: 0361-8609; 1096-8652
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: AbstractMulticentric Castleman disease (MCD) is an uncommon lymphoproliferative disorder for which the best therapeutic option is not yet well established. Immune‐related disorders are rare complications of MCD. We report on an MCD case in a 23‐year‐old patient with extensive abdominal involvement and associated immune hemolytic anemia and Raynaud phenomenon. He was negative for human immunodeficiency virus (HIV) and human herpesvirus‐8 (HHV‐8). After 8 courses of the anti‐CD20 monoclonal antibody (rituximab), the patient achieved complete remission. Interestingly, Raynaud phenomenon disappeared under treatment and no new hemolytic events occurred. Anti‐CD20 antibody treatment could be an attractive therapeutic approach for MCD, mainly when immune‐related disorders are associated. Am. J. Hematol. 78:302–305, 2005. © 2005 Wiley‐Liss, Inc.
  • Zugangsstatus: Freier Zugang